MNTA Momenta Pharmaceuticals Inc.

28.79
+0.61  (+2%)
Previous Close 28.18
Open 27.3
Price To Book 10.32
Market Cap 2,850,876,287
Shares 99,023,143
Volume 959,367
Short Ratio
Av. Daily Volume 1,298,695
Stock charts supplied by TradingView

NewsSee all news

  1. Momenta Provides Year-End 2019 Update and 2020 Outlook

    -- Interim Phase 1 / 2 data of M254 in ITP supports expansion of lower dose cohorts; additional data expected Q2; plan to initiate Phase 2 study in CIDP – -- Nipocalimab (M281) MG study 80% enrolled; readout expected in

  2. Momenta Pharmaceuticals Announces CFO Transition

    CAMBRIDGE, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) ("Momenta" or the "Company"), a biotechnology company focused on discovering and developing novel biologic therapeutics to

  3. Momenta Pharmaceuticals to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Dec. 24, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that Craig Wheeler, President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference.

  4. Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors

    CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors. "Dr. Barlow's

  5. Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1 data due in 2020.
M230 (CSL730)
Healthy volunteers
Phase 2 data due 3Q 2020.
Nipocalimab (M281)
generalized myasthenia gravis (gMG)
Phase 2 data due 2021.
Nipocalimab (M281)
hemolytic disease of the fetus and newborn (HDFN)
Phase 1/2 additional data due 2Q 2020.
M254
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data due YE 2021.
Nipocalimab (M281)
Warm Autoimmune Hemolytic Anemia (wAIHA)

Latest News

  1. Momenta Provides Year-End 2019 Update and 2020 Outlook

    -- Interim Phase 1 / 2 data of M254 in ITP supports expansion of lower dose cohorts; additional data expected Q2; plan to initiate Phase 2 study in CIDP – -- Nipocalimab (M281) MG study 80% enrolled; readout expected in

  2. Momenta Pharmaceuticals Announces CFO Transition

    CAMBRIDGE, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) ("Momenta" or the "Company"), a biotechnology company focused on discovering and developing novel biologic therapeutics to

  3. Momenta Pharmaceuticals to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Dec. 24, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that Craig Wheeler, President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference.

  4. Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors

    CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors. "Dr. Barlow's

  5. Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common

  6. Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the

  7. Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  8. Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results

    CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  9. Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

    CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated